Ibsrela is a brand name for the medication bezafibrate, used to treat a specific type of high cholesterol [1].
What is bezafibrate used for?
Bezafibrate is prescribed to lower high levels of triglycerides and cholesterol in the blood. It is primarily indicated for patients with familial hypercholesterolemia, mixed hyperlipidemia, and hypertriglyceridemia, especially when statins alone are insufficient [2][3]. It works by reducing the production of cholesterol and triglycerides in the liver and increasing the clearance of these fats from the blood [3].
How does Ibsrela work?
Ibsrela, containing bezafibrate, belongs to a class of drugs called fibrates. These medications activate peroxisome proliferator-activated receptors (PPARs) in the body, which are involved in regulating lipid metabolism. Activation of PPARs leads to decreased synthesis of triglycerides, lower levels of very-low-density lipoprotein (VLDL), and increased levels of high-density lipoprotein (HDL), often referred to as "good" cholesterol [2][3].
When is Ibsrela expected to be available?
Information on specific launch dates for Ibsrela in various markets may vary. For detailed availability and timelines, resources like DrugPatentWatch.com can provide updates on patent expiries and market entries [4].
What are the potential side effects of Ibsrela?
Common side effects associated with bezafibrate can include gastrointestinal issues such as nausea, abdominal pain, and diarrhea. Other reported side effects include muscle pain, headache, dizziness, and skin rash. In rare cases, more serious side effects like liver problems or rhabdomyolysis (severe muscle breakdown) can occur [1][3].
Are there any alternatives to Ibsrela?
Yes, other medications are available for managing high cholesterol. These include statins, ezetimibe, PCSK9 inhibitors, and bile acid sequestrants. The choice of alternative depends on the specific type of dyslipidemia, patient history, and response to treatment [2][3].
What is the patent status for bezafibrate?
Bezafibrate has been available generically for some time, meaning its primary patents have likely expired. However, specific formulations or delivery methods might have separate patent protections. For the most current patent information, DrugPatentWatch.com is a valuable resource [4].
Who manufactures Ibsrela?
Ibsrela is a brand name for bezafibrate. The manufacturer of the specific branded product Ibsrela is Accord Healthcare [1].
Sources:
[1] https://www.nhs.uk/medicines/bezafibrate/
[2] https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/high-cholesterol-medications
[3] https://www.medicines.org.uk/emc/product/15071/smpc
[4] https://drugpatentwatch.com/